Lv5
1590 积分 2021-08-17 加入
CDK2 heterobifunctional degraders co-degrade CDK2 and cyclin E resulting in efficacy in CCNE1-amplified and overexpressed cancers
2天前
已完结
Mining the CRBN target space redefines rules for molecular glue–induced neosubstrate recognition
4天前
已完结
A Phase 1 Study of FHD-286, a Dual BRG1/BRM (SMARCA4/SMARCA2) Inhibitor, in Patients With Advanced Myeloid Malignancies
1个月前
已完结
Exploring the next generation of antibody–drug conjugates
1个月前
已完结
Resistance mechanisms and therapeutic strategies of CDK4 and CDK6 kinase targeting in cancer
1个月前
已完结
Synthetic lethality in cancer drug discovery: challenges and opportunities
1个月前
已完结
PRT3789 is a First-in-Human SMARCA2-Selective Degrader that Induces Synthetic Lethality in SMARCA4-Mutated Cancers
2个月前
已完结
Synthetic lethal strategies for the development of cancer therapeutics
3个月前
已完结
Cancer immunology data engine reveals secreted AOAH as a potential immunotherapy
3个月前
已完结
Discovery and preclinical evaluations of TQB3616, a novel CDK4-biased inhibitor
3个月前
已完结
皖公网安备34019202002308
